ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

Shares of ChemoCentryx Inc. soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The company said this is the first new drug to treat the rare autoimmune disease in a decade. ChemoCentryx's stock slipped 68.3% this year, while the broader S&P 500 is up 16.1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug
Shares of ChemoCentryx Inc. soared 80.3% in premarket trading on Friday after the company said that it had received approval from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The company said this is the first new drug to treat the rare autoimmune disease in a decade. ChemoCentryx's stock slipped 68.3% this year, while the broader S&P 500 is up 16.1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.